MIRA PHARMACEUTICALS, INC. MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA, the "Company", "we", "us") is a clinical-stage pharmaceutical
development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related
disorders. The Company holds exclusive rights in the United States, Canada, and Mexico to Ketamir-2, MIRA-55, and SKNY-1, three drug
candidates designed to address significant unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders,
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $1.7M | $3.3M | $1.6M | $2.4M | — |
| SG&A | $8.8M | $4.7M | $6.5M | $3.0M | — |
| Total operating expenses | $10.5M | $8.0M | $8.5M | $7.0M | — |
| Interest expense | $98.9K | $165.7K | $3.5M | $10.2K | — |
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M | — |
| EPS, basic | -1.35 | -0.51 | -0.85 | -0.40 | — |
| EPS, diluted | -1.35 | -0.51 | -0.85 | -0.40 | — |
| Shares, diluted (wtd. avg.) | $23.7M | $15.4M | $13.9M | $17.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $6.3M | $2.8M | — | — | — |
| Short-term investments | $4.7M | — | — | — | — |
| Total current assets | $11.1M | $2.9M | $4.9M | $494.4K | — |
| Total assets | $11.1M | $2.9M | $4.9M | $858.1K | — |
| Accounts payable | $129.2K | $723.3K | $538.6K | $811.7K | — |
| Total current liabilities | $702.1K | $723.3K | $558.1K | $1.4M | — |
| Total liabilities | $702.1K | $723.3K | $558.1K | $1.5M | — |
| Retained earnings | -$39.6M | -$29.1M | -$21.3M | -$9.3M | — |
| Total equity | $10.4M | $2.2M | $4.4M | -$596.2K | $2.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M | -$5.6M | — |
| Stock-based compensation | $6.3M | $1.9M | $2.6M | $1.3M | — |
| Financing cash flow | $8.2M | $3.8M | $8.8M | $3.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014001.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |